Veterans Affairs committee  Mr. Chair, I thank the member for the question. The member is, I believe, referring to the 2009 policy decision made by the U.S. Army. I believe that was in response to some research that I had published that had demonstrated that the drug had been used improperly on a large sc

Veterans Affairs committee  I would say that what is missing from those reports is an acknowledgement of the most important thing with mefloquine and that is that the use of the drug must be discontinued at the onset of psychiatric symptoms. It is this critical warning that I think has been ignored and that

Veterans Affairs committee  Mr. Chair, I thank the member for the question. As I mentioned in my opening brief, the deployment of large numbers of women of reproductive age provides an opportunity—but, really, it forces the issue. It forces, or should force, militaries to reconsider, if they haven't alread